Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Recruiting

Phase 2

BevacizumabBevacizumab In Hereditary Hemorrhagic Telangiectasia

Sponsor:

Hanny Al-Samkari, MD

Code:

NCT04404881

Conditions

Hereditary Hemorrhagic Telangiectasia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Hanny Al-Samkari, MD on 2024-04-23.